Renal Denervation Produces Mixed Results In Small Sham-Controlled Trial
This article was originally published in The Gray Sheet
Executive Summary
Renal denervation with Medtronic’s Symplicity Flex catheter failed to significantly reduce systolic blood-pressure in a sham-controlled trial in patients with mild drug-resistant hypertension, although the per-protocol analysis did show a benefit from renal denervation.
You may also be interested in...
Renal Denervation: Stepping Back To Move Forward
With the announcement that Medtronic is going back to the clinical drawing board after the pivotal SYMPLICITY HTN-3 trial of its renal denervation device failed to meet its primary efficacy endpoint, the industry is taking a cautious but still optimistic stance on the highly touted potential treatment for resistant hypertension.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.